EURETINA 2023: Safety and efficacy through week 48 in the Phase 2a STARLIGHT clinical trial

News
Article
Conference|EURETINA

We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"

The 23rd annual EURETINA Congress is underway in Amsterdam, the Netherlands. We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial."

Here's what he had to say about the meeting and his research.

Audio Transcript

Editor's note - This transcript has been edited for clarity.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
An image of boxing gloves in a ring, hanging over an open flame. ©Image by Jennifer Toomey / MJH Life Sciences using AI

Up for debate: Clinicians take on hot topics at the Congress on Controversies in Ophthalmology

Hattie Hayes;Anat Loewenstein, MD;Baruch Kuppermann, MD, PhD
March 31st 2025
Article

This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An image of an intraocular lens (IOL) being lifted with a surgical device. Accommodative intraocular lens concept image for cataract and refractive surgery. Image credit: ©Wirestock – stock.adobe.com. In the lower right hand side is a photo of Editorial Advisory Board member and article author Jorge L. Alió, MD, PhD, FEBOphth, courtesy of Professor Alió.

Accommodative intraocular lenses: Are they coming back?

Jorge L. Alió, MD, PhD, FEBOphth, FWCRS
March 28th 2025
Article

A resurgence in this IOL technology could create new possibilities in refractive correction

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A phone with the Alcon logo on it, visible against another digital background. Concept image for Alcon company acquisition of Aurion Biotech. Image credit: ©Mojahid Mottakin – stock.adobe.com

Alcon acquires majority interest in cell therapy company Aurion Biotech, provides operational updates

Martin David Harp
March 27th 2025
Article

AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease

A blue eye with a large splash of blue liquid coming out of it. Vitreoretinal surgery ILM dye stain concept. Image credit: ©Sergey Nivens – stock.adobe.com

Internal limiting membrane staining dye ILM-Blue from DORC (Zeiss) receives NMPA approval in China

Hattie Hayes
March 27th 2025
Article

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

© 2025 MJH Life Sciences

All rights reserved.